Replication of the DAPA-CKD (Chronic Kidney Disease) Trial in Healthcare Claims Data

CompletedOBSERVATIONAL

Enrollment

87,727

Participants

Timeline

Start Date

December 13, 2020

Primary Completion Date

June 11, 2021

Study Completion Date

June 11, 2021

Conditions

Chronic Kidney Disease

Interventions

DRUG

Dapagliflozin

Dapagliflozin dispensing claim is used as the exposure group.

DRUG

Sitagliptin

Sitagliptin dispensing claim is used as the reference group.

Trial Locations (1)

Brigham and Women's Hospital, Boston

All Listed Sponsors

lead

Brigham and Women's Hospital

OTHER

NCT04882813 - Replication of the DAPA-CKD (Chronic Kidney Disease) Trial in Healthcare Claims Data | Biotech Hunter | Biotech Hunter